Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

2007 were net of US$42.2 million sales deductions, primarily coupons, wholesaler discounts and rebates, which are expected over time to be approximately 28% of product sales before sales deductions.

All initial launch stocks of VYVANSE totaling US$57.8 million were recognised into revenue during the year to December 31, 2007.

DAYTRANA - ADHD

Product sales for the year to December 31, 2007 were US$64.2 million (2006: US$25.1 million). DAYTRANA's average share of the US ADHD market increased to 2.1% in 2007 compared to 0.8% in 2006 (DAYTRANA was launched in June 2006). US prescriptions of DAYTRANA for the year to December 31, 2007 over 2006 benefited from a full year of demand, 6% growth in the US ADHD market and higher market share. For the six month period to December 31, 2007 prescriptions of DAYTRANA were up 31% compared to the same period in 2006. During September 2007 Shire announced a voluntary market withdrawal of a limited quantity of DAYTRANA patches following feedback from patients and caregivers who had experienced difficulty in removing the release liner. Patches are now being manufactured using an enhanced process, which Shire believes offers improved ease of use when peeling off the release liner.

On January 9, 2008 the US Food and Drug Administration ("FDA") issued a warning letter to Noven Pharmaceuticals Inc. ("Noven"), which related to Noven's manufacture of DAYTRANA. Further regulatory action could result if the FDA's concerns are not satisfied fully. Noven submitted a response to the FDA on January 30, 2008 and the FDA responded on March 14, 2008 indicating that Noven's responses appear to be satisfactory. It is expected that the FDA will perform a follow-up FDA inspection of Noven's manufacturing plant to ensure compliance.

The addition of VYVANSE combined with ADDERALL XR and DAYTRANA's market share helped Shire grow its total share of the US ADHD market to 31.1% at December 31, 2007 compared to 28.0% at Decem
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... OTTAWA, Canada, and BELLINGHAM, Washington, USA (PRWEB) May 26, ... has signed a formal partnership with the ... Ottawa Centre for Extreme and Quantum Photonics. The center ... in the field of photonics, and will be only ... Arthurs, CEO of SPIE, the international society for ...
(Date:5/26/2015)... 2015 Regenestem Network has ... clinic in Buenos Aires, Argentina. The clinic will be ... specialist. Pastrana has assembled a multidisciplinary team of medical ... her state-of-the-art Puerto Madero office. , The new ... phase IV clinical studies in cellular therapies, and establish ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 WORMS, ... Grace & Co. (NYSE: GRA) announces that its ... manufacturing practice (GMP) certification from EXCiPACT™, an independent ... pharmaceutical excipients. , All three Grace ... pharmaceutical grade excipient silica gels have now received ...
(Date:5/26/2015)... 2015 Innovacyn, a leader in ... human and animal health industries, announced today the ... of Agriculture College Scholarship Award. The scholarship was ... a passionate commitment to the agriculture industry through ... winners, Alexis Pedrow from Anderson County Jr/Sr High ...
Breaking Biology Technology:Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 2Innovacyn Announces Winners Of This Year’s Vetericyn® College Scholarship Award 3
... 17 Simbionix, the world,s leading,developer of medical simulation ... for distribution of Simbionix,s simulators and related,products. , ... of Johnson & Johnson, operates in,Russia, the Ukraine, and ... & Johnson LLC will have exclusive rights to distribute,Simbionix,s ...
... Growing Demand , ... Arlington, Va. (PRWEB) April 16, ... meet the growing demand for food, biofuels and materials if public ... take a more holistic approach to the solution, William S. ...
... Understanding the Fundamental Mechanism of Angiogenesis is More ... AAmgen Launches Angiogenesis Website THOUSAND OAKS, Calif., April ... today announced that results from several preclinical studies ... at the 2009 American Association for Cancer Research ...
Cached Biology Technology:Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries 2DuPont Leader: Agriculture is Up to Global Productivity Challenge 2DuPont Leader: Agriculture is Up to Global Productivity Challenge 3DuPont Leader: Agriculture is Up to Global Productivity Challenge 4Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 2Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 3Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 4Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 5Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 6Preclinical Data From Amgen's Oncology Pipeline to be Presented at AACR 7
(Date:5/26/2015)... DUBLIN , May 26, 2015 ... has announced the addition of the "Saudi ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... Saudi Arabia is projected to grow ... This high growth is attributed to the surging ...
(Date:5/25/2015)... -- Australia,s market for wearable technologies is considered to be ... of several trials and prototypes. The release of the ... ignite interest in wearables as well as accelerate sales ... This in turn will spur greater innovation from other ... vendors and distributors. Photo - ...
(Date:5/22/2015)... 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... be ending its promotional pricing and making the Wocket generally ... Laurence Savin , Head of Marketing said, "We,ve extended the ... the end of May. To get your wocket at this ... open the store on June 1, you,ll receive a unique ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3
... The International HapMap Project was initiated with the primary ... basis for human diseases. To coordinate with the ... journal Genome Research is announcing a special ... to studies using these data to provide insight into ...
... with the primary goal of facilitating medical studies and ... coordinate with the journal Nature 's publication describing ... announcing a special issue entitled "Human Genome Variation," which ... provide insight into human biology and disease. , ...
... drug designAs part of a $4.88 million grant from ... University of Rochester Medical Center will join a team ... a living cell. By wiring diagram, researchers mean a ... their function, but also of the interplay between them. ...
Cached Biology News:Housecat-sized Siberian tiger cubs get collared 2Housecat-sized Siberian tiger cubs get collared 3Housecat-sized Siberian tiger cubs get collared 4Studies on human genome variation provide insight into disease 2Studies on human genome variation provide insight into disease 3Studies on human genome variation provide insight into disease 4New study to explore cellular circuitry 2New study to explore cellular circuitry 3
EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
... for interferons are cytopathic effect inhibition assays, also ... types include; tissue culture supernatents; serum from PK ... one unit is defined as the quantity of ... effect of viral infection by 50%. ...
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
... interferons are cytopathic effect inhibition assays, also known ... include; tissue culture supernatents; serum from PK studies ... unit is defined as the quantity of interferon ... of viral infection by 50%. All ...
Biology Products: